Effectivity of Protein Purified Derivative Treatment for Anogenital Warts in HIV Patient

Research Design Research on the response to administration of intralesional PPD-2TU therapy in warts to changes in levels of various cytokines locally and systemically. Data, Data Collection Techniques and Data Sources The data used is primary data. Primary data is the result of examination anogenital warts patients who were then given PP2-TU therapy at varying doses, blood serum and histopathological preparations are taken before injection and 3 weeks after the injection. Sample Taking/Selection The research sample was anogenital warts patients who were treated at the Infection Polyclinic Sexually Transmitted Hospital Dr. Hasan Sadikin Bandung, using consecutive sampling for each group, 15 anogenital warts patients with and 15 patient without HIV infection were given purified protein derivative injection. Data Validity and Reliability The validity of laboratory examination data can be guaranteed due to inspection. Laboratory work is carried out in the clinical pathology and anatomical pathology laboratories of the Hospital Dr Hasan Sadikin who has international standards. Independent variable: Patients with anogenital warts Dependent variables: Clinical response, levels of IFN-α, IFN-γ, and IL-2 in the blood and tissue.